DelveInsight’s ’Essential Thrombocythemia (ET)-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Essential Thrombocythemia (ET), historical and forecasted epidemiology as well as the Essential Thrombocythemia (ET) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Essential Thrombocythemia (ET) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Essential Thrombocythemia (ET) market size from 2017 to 2030. The Report also covers current Essential Thrombocythemia (ET) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan



Study Period: 2017–2030
Essential Thrombocythemia (ET) Disease Understanding and Treatment Algorithm
Essential Thrombocythemia (ET) Overview
According to the MPN Research Foundation, Essential Thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) characterized by an increased number of platelets in the blood. The overproduction (megakaryocytic hyperplasia) of platelet-forming cells, called “megakaryocytes,” in the marrow results in the release of too many platelets into the blood.
The term “essential” indicates that the increase in platelets is an inherent problem of the blood cell production in the bone marrow and “Thrombocythemia” refers to an excess of platelets in the blood. Also, the increased platelet count may result in the blockage in blood vessels (thrombus), splenomegaly, and hemorrhagic episodes. Most cases of ET are not inherited, and it arises from gene mutations that occur in early blood-forming cells after conception. However, in very rare cases, ET is inherited in an autosomal dominant pattern and known as familial Essential Thrombocythemia.

The typical pattern of ET onset is bimodal, with one peak occurring during young adulthood in females and the other peak occurring between the ages of 50–70 years in both males and females. The incidence of ET is around 1.5–2 times higher in females as compared to males.
Essential Thrombocythemia (ET) Diagnosis
The diagnosis of ET is based on the complete blood count, blood smear examination, genetic and bone marrow testing. Some of the patients may be asymptomatic and found to have an increased platelets count. By carefully examining the results of the above-mentioned diagnostic tests and by reviewing the patient’s clinical history and symptoms, a physician can diagnose ET.
Continued in the report?..
Essential Thrombocythemia (ET) Treatment
The objective of the treatment of ET is to prevent vascular complications such as thrombotic and hemorrhagic events because they are the leading causes of morbidity and mortality. The treatment strategy mostly depends on whether the patient is at low or high risk for thrombosis as risk stratification is used to determine the need for the patient to undergo the procedure. Generally, the low-risk patients are young with no prior thrombosis, whereas high-risk patients are older (over age 60) with a previous history of thrombosis.
Low-risk patients are recommended aspirin if there are no significant contraindications for the same. There should be a careful consideration of the possibility of acquiring von Willebrand disease when platelets are more than 1,000 _ 109/L because, in the setting of abnormal von Willebrand laboratory parameters, aspirin should not be used. Aspirin is also the indicated treatment for a patient with microvascular thrombosis such as erythromelalgia. Also, antiplatelet and cytoreductive therapy is adopted for a high-risk patient.
Hydroxyurea is generally considered as the first-line drug for cytoreductive therapy. Anagrelide, on the other hand, is a second-line therapy used to reduce platelet count. Other drugs used in ET include radioactive phosphorous, pipobroman, interferon, and busulfan. These are still used in older patients who cannot tolerate hydroxyurea (Ashorobi & Gohari, 2019). There are currently four drugs to consider as second-line therapy in ET: pegylated interferon-_ (IFN-_), busulfan, anagrelide, and pipobroman. Among these, the current choice for second-line therapy is pegylated IFN-_ (starting dose 90 mcg SC weekly).
European LeukemiaNet recommends hydroxycarbamide (HC) as the first-line therapy but advises caution in patients <40 years. Anagrelide (Xagrid) is licensed in Europe for patients with ET intolerant/refractory to HC, and in some countries (i.e., USA, Japan) it is authorized as first-line therapy.
Essential Thrombocythemia (ET) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of Essential Thrombocythemia (ET), Total Prevalence of Essential Thrombocythemia Based on Symptoms, Gender-specific Diagnosed Prevalence of Essential Thrombocythemia, Age-specific Diagnosed Prevalence of Essential Thrombocythemia, Prevalence of Essential Thrombocythemia based on Risk, and Gene Mutation Specific Prevalence of Essential Thrombocythemia scenario of ET in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Key Findings

  • As per DelveInsight’s analysis, the total Prevalent Population of Essential Thrombocythemia (ET) in the 7MM was found to be 232,688 in 2017. The estimates higher prevalence of Essential Thrombocythemia (ET) in the United States with 142,635 cases in 2017.
  • According to DelveInsight’s analysis, it has been observed that ET is mostly diagnosed in the age group of 60-80.
  • Among EU5, France shows a higher prevalence of ET followed by Germany and the UK, Italy, and Spain respectively.
  • Japan accounts second among the 7MM in terms of prevalent cases with 19,946 cases among the 7MM.


Essential Thrombocythemia (ET) Epidemiology
The epidemiology segment also provides the Essential Thrombocythemia (ET) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Essential Thrombocythemia (ET) Drug Chapters
The drug chapter segment of the Essential Thrombocythemia (ET) report encloses the detailed analysis of ET marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Essential Thrombocythemia (ET) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.
Essential Thrombocythemia (ET) Marketed Drugs
Agrylin/Xagrid: Shire
Agrylin (anagrelide HCI) is the first drug approved for the treatment of Essential Thrombocythemia (ET). It is a platelet-reducing agent, with chemical name 6, 7-dichloro- 1, 5-dihydroimidazo [2, 1-b] quinazolin-2(3H)-1 monohydrochloride monohydrate. Bristol-Myers Squibb originally developed the drug, but in 1999, Roberts Pharmaceutical purchased all rights of Agrylin from them, and later Shire Plc acquired Roberts Pharmaceutical. Hence, now Shire Plc holds the rights for agrylin. The drug is approved under the name xagrid in Europe, and as agrylin in the US and Japan.
Products detail in the report?

Thromboreductin: AOP Orphan Pharmaceuticals
Thromboreductin is an innovative treatment option for patients afflicted by Essential Thrombocythemia (ET), a rare but severe bone marrow disease. The active ingredient in thromboreductin, which helps in lowering the blood platelet count and reduces the risk of complications, is anagrelide. This drug is not associated with a possible risk of leukemogenesis, as is currently the case with cytostatic agents. Treatment with this drug, if successful, could help patients have an almost normal life expectancy.
Products detail in the report?
Essential Thrombocythemia (ET) Emerging Drugs
Ropeginterferon alfa-2b (P1101): PharmaEssentia
Ropeginterferon alfa-2b (P1101) is a novel, long-acting, mono-pegylated proline interferon with improved pharmacokinetic properties offering improved tolerability and convenience. It is discovered and manufactured by PharmaEssentia in a Taichung plant, which was cGMP certified by EMA in January 2018. Ropeginterferon alfa-2b is designed to be the purer interferon-alpha designed; other interferon alphas on the market currently include PEG-Intron (Merck) and Pegasys (Roche).
Products detail in the report?
Jakavi (ruxolitinib): Novartis
Jakavi (ruxolitinib) is an oral JAK1/JAK2 inhibitor with clinical benefit in patients with other MPNs, myelofibrosis (MF), ET, and PV. It is approved by the European Commission for the treatment of adult patients with PV who are resistant to or intolerant of hydroxyurea and for the treatment of disease-related splenomegaly or symptoms in adult patients with primary MF (also known as chronic idiopathic MF), post-PV MF or post-ET MF. The exact indication for Jakavi varies by country. Novartis licensed ruxolitinib from Incyte Corporation for development and commercialization outside the United States. Jakavi is marketed in the United States by Incyte Corporation as Jakafi for patients with PV who have had an inadequate response to or are intolerant of hydroxyurea.
Products detail in the report?
Bomedemstat (IMG-7289): Imago BioSciences
Bomedemstat (IMG-7289) is a small molecule discovered by Imago BioSciences that inhibits lysine-specific demethylase 1 (LSD1 or KDM1A), an enzyme essential for the production and normal function of megakaryocytes and self-renewal of malignant hematopoietic stem or progenitor cells. Megakaryocytes are the primary producer of platelets and cytokines that drive essential thrombocythemia pathogenesis. Currently, bomedemstat is being tested in clinical studies as a potentially disease-modifying monotherapy for MF, ET, and related indications.
Products detail in the report?
List to be continued in the report?

Essential Thrombocythemia (ET) Market Outlook
ET is associated with an increased risk of thrombohemorrhagic complications and transformation to myelofibrosis (MF) or acute leukemia (AL). Cytoreductive therapy (CRT) is used to reduce thrombosis and hemorrhage in high-risk ET. The CRT treatment includes the use of CRT, anagrelide, hydroxycarbamide, busulfan, interferon-_ (IFN), pegylated interferon, pipobroman and sodium phosphate (P32).
Low-risk patients are recommended aspirin if there are no significant contraindications for the same. There should be a careful consideration of the possibility of acquiring von Willebrand disease when platelets are more than 1,000 _ 109/L because, in the setting of abnormal von Willebrand laboratory parameters, aspirin should not be used. Aspirin is also the indicated treatment for a patient with microvascular thrombosis such as erythromelalgia. Also, antiplatelet and cytoreductive therapy is adopted for a high-risk patient.
Pregnant patients with ET are recommended to use low molecular weight heparin during pregnancy for 6 weeks after delivery in addition to cytoreduction with pegylated interferon. Also, in pregnant females who have extremely high platelets, the action of interferon is slow to bring down the platelets; plateletpheresis was reported to be an option to reduce the number of platelets.
Apart from this, the other treatment recommendations in young women wishing to become pregnant or are pregnant include once-daily aspirin for “very low-risk” or “low-risk” disease and pegylated IFN-_ for high-risk disease. Both aspirin and IFN-_ therapy are safe for use during pregnancy and might be associated with lower miscarriage rates in women with ET.
According to DelveInsight, Essential Thrombocythemia (ET) 7MM is expected to change in the study period 2017–2030.

Key Findings

  • The market size of Essential Thrombocythemia (ET) in the 7MM was found to be USD 616.05 million in 2017.
  • Among the 7MM countries, the United States had the highest market size of Essential Thrombocythemia (ET) in 2017, which accounts for approximately 74.03% of the total market.


The United States Market Outlook
This section provides the total Essential Thrombocythemia (ET) market size and; market size by therapies in the United States.
EU-5 Market Outlook
The total Essential Thrombocythemia (ET) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Essential Thrombocythemia (ET) market size and market size by therapies in Japan are provided.
Essential Thrombocythemia (ET) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Essential Thrombocythemia (ET) market or expected to get launched in the market during the study period 2017–2030. The analysis covers Essential Thrombocythemia (ET) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Essential Thrombocythemia (ET) Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Essential Thrombocythemia (ET) emerging therapies.
Reimbursement Scenario in Essential Thrombocythemia (ET)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the Essential Thrombocythemia (ET) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report

  • The report covers the descriptive overview of Essential Thrombocythemia (ET), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Essential Thrombocythemia (ET) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Essential Thrombocythemia (ET) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Essential Thrombocythemia (ET) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Essential Thrombocythemia (ET) market.



Report Highlights

  • In the coming years, Essential Thrombocythemia (ET) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Essential Thrombocythemia (ET) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Essential Thrombocythemia (ET). Launch of emerging therapies will significantly impact the Essential Thrombocythemia (ET) market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.


Essential Thrombocythemia (ET) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Essential Thrombocythemia (ET) Pipeline Analysis
  • Essential Thrombocythemia (ET) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Essential Thrombocythemia (ET) Report Key Strengths

  • Eleven Years Forecast
  • 7MM Coverage
  • Essential Thrombocythemia (ET) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake



Essential Thrombocythemia (ET) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers


Key Questions
Market Insights:

  • What was the Essential Thrombocythemia (ET) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Essential Thrombocythemia (ET) total market size as well as market size by therapies across the 7MM during the forecast period (2020–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Essential Thrombocythemia (ET) market size during the forecast period (2020–2030)?
  • At what CAGR, the Essential Thrombocythemia (ET) market is expected to grow at the 7MM level during the forecast period (2020–2030)?
  • What would be the Essential Thrombocythemia (ET) market outlook across the 7MM during the forecast period (2020–2030)?
  • What would be the Essential Thrombocythemia (ET) market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Essential Thrombocythemia (ET)?
  • What is the historical Essential Thrombocythemia (ET) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Essential Thrombocythemia (ET) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Essential Thrombocythemia (ET)?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Essential Thrombocythemia (ET) during the forecast period (2020–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Essential Thrombocythemia (ET) along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Essential Thrombocythemia (ET) in the US and Europe?
  • What are the Essential Thrombocythemia (ET) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Essential Thrombocythemia (ET)?
  • How many therapies are developed by each company for the treatment of Essential Thrombocythemia (ET)?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Essential Thrombocythemia (ET)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Essential Thrombocythemia (ET) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Essential Thrombocythemia (ET) and their status?
  • What are the key designations that have been granted for the emerging therapies for Essential Thrombocythemia (ET)?
  • What are the 7MM historical and forecasted market of Essential Thrombocythemia (ET)?



Reasons To Buy
_ The report will help in developing business strategies by understanding trends shaping and driving the Essential Thrombocythemia (ET).
_ To understand the future market competition in the Essential Thrombocythemia (ET) market and Insightful review of the key market drivers and barriers.
_ Organize sales and marketing efforts by identifying the best opportunities for Essential Thrombocythemia (ET) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
_ Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
_ Organize sales and marketing efforts by identifying the best opportunities for Essential Thrombocythemia (ET) market.
_ To understand the future market competition in the Essential Thrombocythemia (ET) market.